Format

Send to

Choose Destination
Neurologia. 2017 Nov 28. pii: S0213-4853(17)30321-3. doi: 10.1016/j.nrl.2017.09.005. [Epub ahead of print]

Intravenous immunoglobulin G as adjuvant treatment in drug-resistant childhood epilepsy.

[Article in English, Spanish]

Author information

1
Departamento de Neurología Pediátrica, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México. Electronic address: gocz26@gmail.com.
2
Departamento de Neurología Pediátrica, Centro Médico Nacional 20 de Noviembre, ISSSTE, Ciudad de México, México.
3
Departamento de Ortopedia, Centro Médico ABC, Ciudad de México, México.

Abstract

BACKGROUND:

Epilepsy is the most common neurological disease in childhood; depending on the definition of drug-resistant epilepsy, incidence varies from 10% to 23% in the paediatric population. The objective of this study was to account for the decrease in the frequency and/or monthly duration of epileptic seizures in paediatric patients with drug-resistant epilepsy treated with antiepileptic drugs, before and after adding intravenous immunoglobulin G (iIV IgG).

METHODS:

This is an analytic, observational, retrospective case-control study. We studied paediatric patients with drug-resistant epilepsy who were treated with IV IgG at the Centro Médico Nacional 20 de Noviembre, in Mexico City, from 2003 to 2013.

RESULTS:

One hundred and sixty seven patients (19.5%) had drug-resistant epilepsy and 44 (5.1%) started adjuvant treatment with IV IgG. The mean age of patients at the beginning of treatment was 6.12 years±5.14); aetiology was structural acquired in 28 patients (73.6%), genetic in 5 (13.1%), immune in 1 (2.6%), and unknown in 4 (10.5%). At 2 months from starting IV IgG, seizure duration had reduced to 66.66%; the frequency of seizures was reduced by 64% at 4 months after starting treatment (P<.001).

CONCLUSIONS:

According to the results of this study, intravenous immunoglobulin may be an effective therapy for reducing the frequency and duration of seizures in paediatric patients with drug-resistant epilepsy.

KEYWORDS:

Crisis epiléptica; Drug-resistant epilepsy; Epilepsia farmacorresistente; IV immunoglobulin G; Inmunoglobulina G iv; Seizures

PMID:
29196143
DOI:
10.1016/j.nrl.2017.09.005
Free full text

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center